生物製药 CDMO 的全球市场增长机会

本报告对全球生物製药CDMO市场进行调研分析，涵盖北美、欧洲、亚太三大区域，对2023年至2028年六年的市场收入进行预测，并进行详细的细分市场分析。

内容

战略要务

• 为什么越来越难成长？
• 战略要务 8 (TM)
• 三大战略要务对全球生物製药 CDMO 行业的影响
• 增长机会推动增长 Pipeline Engine(TM)

增长机会分析

• 分析范围
• 按产品类型进行市场细分
• 按细胞表达系统类型细分市场
• 按服务类型进行市场细分
• 生物製药 CDMO 市场的主要区域竞争对手
• 增长动力
• 抑制增长的因素

成长环境-生物製药CDMO市场

• 生物製药管线概览
• 生物製药 CDMO 商业模式 - 价值链扩展
• 概述主要 CDMO 活动以支持促进精准医疗的下一代生物製药模式
• 生物仿製药上市对 CDMO 的影响
• 生物製药 CDMO 行业的主要新趋势
• 为新进入者铺平道路的新模式
• 已上市生物製药的产品分布（2022 年）
• 生物工艺技术分布 - 用于哺乳动物製造的一次性生物反应器 (SUB) 和固定床多用途生物反应器 (MUB)
• 生物製造能力的区域分布

增长机会分析 - 生物製药 CDMO 行业

• 全球生物製药 CDMO 市场的主要增长指标
• 预测框架 - 生物製药 CDMO 的市场规模
• 预测方法 - 生物製药 CDMO 市场
• 预测假设和考虑因素 - 生物製药 CDMO 市场
• 收入预测 - 全球生物製药 CDMO 市场
• 收入预测分析 - 全球生物製药 CDMO 市场
• 按产品类型预测收入
• 收入预测分析：按产品类型
• 按细胞表达系统类型划分的收入预测
• 哺乳动物表达系统的利润预测分析
• 微生物表达系统盈利预测分析
• 其他表达系统的收入预测分析
• 收入分配：按服务类型
• 竞争环境
• 收入份额估算 - 生物製药 CDMO 市场进入者
• 收入份额分析 - 生物製药 CDMO 市场进入者

成长机会

• 增长机会 1：在欧洲建立 CGT 製造和销售能力
• 增长机会 2：改善和扩大亚洲的病毒载体製造能力
• 增长机会 3：活性生物治疗产品（微生物组）的製造能力
• 增长机会 4：在生物製造中采用 AI 和数字孪生
• 增长机会 5：新疗法的发现和临床前服务
• 增长机会 6：专用于 CGT 的 PAT 服务

下一步

Value Chain Expansion to Support Next generation Biologics Drives Future Growth Potential

This research service provides an overview of the global biologics contract development and manufacturing organization (bio-CDMO) market and a 6-year market revenue forecast (2023 to 2028). The geographic scope covers three key regions, namely North America (NA); Europe; and Asia-Pacific (APAC). The report offers a detailed segment analysis of the bio-CDMO market, including emerging business models such as reserved capacity and contract research development and manufacturing organization (CRDMO) services that are set to dominate the traditional fee-for-service manufacturing services space. The market segments cover drug type (drug substance and drug products) and cell expression type (microbial, mammalian, and other modalities). The other modalities segment includes cell-free expression systems, such as nucleic acid-based products and insect- and plant-based expression systems. For the purpose of this study, the bio-CDMO market forecast includes services encompassing drug development and manufacturing processes, such as product development (R&D) services, analytical support, and manufacturing and packaging services, into one integrated process (from drug development through manufacturing).

The industry shift toward biologics is boosting product pipelines and adoption, leading to more demand for biologics manufacturing capability and capacity expansion. Also, emerging biopharma companies hold two-thirds of the molecules in the R&D pipeline but have limited muscle to develop and commercialize these products. Bio-CDMOs can provide the agility and flexibility required for next-generation modalities such as CGT as they can use their modular facilities for multiple products and clients, which is a challenge for biopharma companies that build capabilities in-house. Big pharma is, therefore, increasingly choosing to outsource complex development and manufacturing processes and de-risking their supply chain instead of building more in-house manufacturing capacity. The transition of CDMOs to CRDMOs is leading them to offer end-to-end services. This positions competitors to partner with biopharmaceutical companies for their research, development, and manufacturing needs-from discovery to commercialization. While the COVID-19 pandemic has led to drug supply shortages, the pharmaceutical industry in general is moving toward right shoring, which involves keeping parts of the supply chain and processes in strategic locations to deliver the desired combination of cost and efficiency. CDMOs are playing a critical role in achieving supply chain resiliency.

Table of Contents

Strategic Imperatives

• Why is it Increasingly Difficult to Grow?
• The Strategic Imperative 8™
• The Impact of the Top Three Strategic Imperatives on the Global Biologics Contract Development and Manufacturing Organization (Bio-CDMO) Industry
• Growth Opportunities Fuel the Growth Pipeline Engine™

Growth Opportunity Analysis

• Scope of Analysis
• Market Segmentation by Product Type
• Market Segmentation by Cell Expression System Type
• Market Segmentation by Service Type
• Key Regional Competitors in the Bio-CDMO Market
• Growth Drivers
• Growth Restraints

Growth Environment-Bio-CDMO Market

• Biologics Pipeline Overview
• Bio-CDMO Business Model-Value Chain Expansion
• Overview of Key CDMO Activities to Support the Next-gen Biologics Modalities Driving Precision Medicine
• Impact of Biosimilar Launches on CDMOs
• Key Emerging Trends in the Bio-CDMO Industry
• New Modalities Paving the Way for New Entrants
• New Modalities Paving Way for New Entrants
• Product Distribution of Marketed Biologics in 2022
• Distribution of Bioprocessing Technique-Single-use Bioreactors (SUB) and Fixed Multiuse Bioreactors (MUB) for Mammalian-based Manufacturing
• Regional Distribution of Total Biomanufacturing Capacity

Growth Opportunity Analysis-Bio-CDMO Industry

• Key Growth Metrics for the Global Bio-CDMO Market
• Forecast Framework-Bio-CDMO Market Sizing
• Forecast Methodology-Bio-CDMO Market
• Forecast Assumptions and Considerations-Bio-CDMO Market
• Revenue Forecast-Global Bio-CDMO Market
• Revenue Forecast Analysis-Global Bio-CDMO Market
• Revenue Forecast by Product Type
• Revenue Forecast Analysis by Product Type
• Revenue Forecast by Cell Expression System Type
• Revenue Forecast Analysis for Mammalian Expression Systems
• Revenue Forecast Analysis for Microbial Expression Systems
• Revenue Forecast Analysis for Other Expression Systems
• Revenue Split by Service Type
• Competitive Environment
• Revenue Share Estimation-Top Bio-CDMO Market Participants
• Revenue Share Analysis-Top Bio-CDMO Market Participants

Growth Opportunity Universe

• Growth Opportunity 1: Building CGT Manufacturing and Distribution Capabilities in Europe
• Growth Opportunity 2: Improving and Expanding Viral Vector Manufacturing Capabilities in Asia
• Growth Opportunity 3: Live Biotherapeutic Products (Microbiome) Manufacturing Capabilities
• Growth Opportunity 4: Adoption of AI and Digital Twins in Biomanufacturing
• Growth Opportunity 5: Discovery and Preclinical Services for New Modalities
• Growth Opportunity 6: Purpose-built PAT Services for CGT

Next Steps

• Your Next Steps
• Why Frost, Why Now?
• List of Exhibits
• Legal Disclaimer